Statement of-Continued Bain, James A., Ph. D., director, Division of Basic Health Sciences, Brennan, Bruce J., vice president and general counsel, Pharmaceutical Brill, Dr. Henry, chairman, Committee on Alcoholism and Drug Chayet, Neil L., lecturer in legal medicine at the Boston University Cole, Dr. Jonathan O., chairman, Committee for Effective Drug Corman, Hon. James C., a Representative in Congress from the Page 449 461 231 275 310 65 David, Clifford C., legislative counsel, Smith Kline & French Laboratories_ de la Garza, Hon. Kika, a Representative in Congress from the State of Texas. Dean, John W., III, Associate Deputy Attorney General, Department of Justice.__. Denney, Hon. Robert V., a Representative in Congress from the State Dobbs, Dr. Dorothy, Director, Marketed Drugs Division, Bureau of 264 215 79 665 340, 493 Egeberg, Dr. Roger O., Ássistant Secretary for Health and Scientific 171 171, 340 Farabee, Dr. Dale, secretary, National Association of State Mental Farnsworth, Dana L., director, University Health Services, Harvard Fletcher, Donald K., manager of distribution protection, Smith Freedman, Dr. Daniel X., professor and chairman, Department of 518 549 264 419, 429 Freeland, Michael E., associate director, National Association for Gallagher, Hon. Cornelius E., a Representative in Congress from the Giaimo, Hon. Robert N., a Representative in Congress from the State Gibson, Dr. Merle, Director, New Drugs Division, Bureau of Drugs, Goddard, Dr. James L., on behalf of the American Public Health Goodrich, William, General Counsel, Bureau of Drugs, Food and 295 516 205 340 255 340, 493 Griffith, Dr. John D., assistant professor, Psychiatry and Pharma- 455 Hanna, Hon. Richard T., a Representative in Congress from the State of California.... Griffiths, Hon. Martha W., a Representative in Congress from the 659 208 Ingersoll, John E., Director, Bureau of Narcotics and Dangerous Hunt, Hon. John E., a Representative in Congress from the State of 329 79, 82, 675 Jaffe, Dr. Jerome H., associate professor of psychiatry, University of 320 Statement of-Continued Jennings, Dr. John, Acting Director, Bureau of Drugs, Food and Drug Administration, Public Health Service, Department of Health, Education, and Welfare. Page 340, 493 Johnson, Hon. Harold T. (Bizz), a Representative in Congress from Klein, Dr. Donald F., director of research, Hillside Hospital, Glen Kline, Dr. Nathan S., New York, N. Y. Lewis, Dr. Edward, Chief Medical Officer, Bureau of Narcotics and Lipton, Dr. Morris A., professor and chairman, Department of Psy- Mark, Ralph and Frances, Poughkeepsie, N. Y Meyer, Dr. Roger, School of Medicine, Boston University, former chief, Center for Studies of Narcotics and Drug Abuse, National Institute of Mental Health_ 64 575 386 79, 675 447 524 666 482 556 Mikva, Hon. Abner J., a Representative in Congress from the State of Miller, Dr. Morton G., Associate Director for Special and Collabora- Mink, Hon. Patsy T., a Representative in Congress from the State of Mitchell, Hon. John N., Attorney General, Department of Justice, 287 171 216 79 419, 437 Moss, Sanford, in behalf of American Psychiatric Association.. Patton, William D., assistant general counsel, Pharmaceutical Manu- 661 461 Pepper, Hon. Claude, a Representative in Congress from the State of 579 Peterson, Harry N., attorney, legislative department, American 231 226 77 357 Pettis, Hon. Jerry L., a Representative in Congress from the State of Podell, Hon. Bertram L., a Representative in Congress from the State Roberts, Carl, director, legal division, American Pharmaceutical Schnibbe, Harry C., executive director, National Association of State Schuster, Charles R., Ph. D., associate professor of psychiatry and Speiser, Lawrence, director, Washington (D.C.) Office, American Civil Stoddard, Ezekial G., special counsel, Pharmaceutical Manufacturers 518 568 79, 675 297 461 Thompson, Hon. Frank, Jr., a Representative in Congress from the 74 Van Deerlin, Hon. Lionel, a Representative in Congress from the State of California_ 62 Vigorito, Hon. Joseph P., a Representative in Congress from the State of Pennsylvania__ 76 Waldie, Hon. Jerome R., a Representative in Congress from the State of California_. 662 West, Dr. Louis Jolyon, trustee, American Psychiatric Association.. Wilson, Hon. Charles H., a Representative in Congress from the State of California.. 419 68 Statement of-Continued Woods, William E., Washington representative, National Association Wright, Mrs. J. Skelly, secretary, National Association for Mental Page 411 295 171, 174 Yolles, Dr. Stanley F., Director, National Institute of Mental Health, American Academy of Pediatrics, Robert G. Frazier, M.D., executive Changes suggested in H.R. 13743, "The Controlled Depressant Letter dated March 11, 1960, to Chairman Jarman re present "Pharmacognosy and Chemistry of 'Canabis sativa" ", by Norman American Psychiatric Association: Barton, Walter E., M.D., medical director, letter dated June 16, 752 811 828 241 364 383 367 810 Curriculum vitae Daniel X. Freedman, M.D.. 436 Position paper on drug abuse and the need to separate medical 425 426 541 Ayd, Dr. Frank J., Jr., biographical sketch__- 831 Burks, Thomas F., Ph. D., assistant professor, School of Medicine, 849 executive director, letter dated March 17, 1970, to Subcommittee on 751 Council of Health Organizations: Article from New York Times entitled "3 Health Groups Combine 528 525 531 Extract from the proceedings of the Council of Health Organiza- man__. Daniel, Hon. Price, former U.S. Senator and Governor of Texas, statement with "The Illicit Narcotics Traffic," Senate Report No. 1440, dated January 23, 1956, attached. 527 731 De Jong, Jacob, M.D., psychiatrist, Newtown, Conn., letter dated 832 726 Eli Lilly & Co., H. F. DeBoest, vice president, corporate affairs, statement._. 756 Additional material submitted for the record by-Continued Ferraro, Douglas P., Ph. D., associate professor, Department of Psychology, University of New Mexico, letter dated March 11, 1970, to Congressman Manuel Lujan of New Mexico, with forwarding letter. Hanna, Hon. Richard T., a Representative in Congress from the State Article from the Santa Ana (Calif.) Register entitled "No Knock Article from the Los Angeles (Calif.) Times entitled " 'No-Knock' Health, Education, and Welfare Department: Characteristics of amphetamine drug dependence.. Letter dated March 3, 1970, from Secretary Finch to Chairman Letter dated March 30, 1970, from Dr. Roger O. Egeberg, to Letter dated April 30, 1970, from M. J. Ryan, Acting Director, Status of feneluramine__ Usefulness of amphetamines in epilepsy- Usefulness of amphetamines in hospitalized psychopaths... Hoffman-La Roche Inc., Dr. V. D. Mattia, president and chief executive officer: Page 848 214 214 501 180 705 202 507 505 496 496 Statement.. Supplemental statement.. Hollister, Leo E., M.D., associate chief of staff, Veterans' Administration Hospital, Palo Alto, Calif., statement 767 776 747 Hunt, Hon. John E., a Representative in Congress from the State of New Jersey, condensed excerpts of testimony of John E. Ingersoll, Director, Bureau of Narcotics and Dangerous Drugs, on the subject of drug abuse S. 3246.. Institute of Living, Research Laboratories, Bernard C. Glueck, Jr., M.D., director of research, letter dated February 2, 1970, to Chairman Staggers Irwin, Samuel, Ph. D., professor of pharmacology, Department of Psychiatry, University of Oregon Medical School, letter dated February 19, 1970, to Mr. W. E. Williamson, clerk, House Committee on Interstate and Foreign Commerce, with attached papers entitled "Controlled Dangerous Substances Act" and "Drugs of Abuse: Their Actions and Relative Hazard Potential”. Justice Department: 332 811 836 Actual case which points out the need for agents to have the 125 Alternative penalties... 90 Depressant and stumulant drugs; proposed listing of additional Dangerous Drugs to implement and administer the proposed 147 Estimated registration fees - - - - 720 Justification for placement of alphacetylmethadol in schedule I 715 92 Members of the Scientific Advisory Committee on Drugs. 154 106 95 Additional material submitted for the record by-Continued White House Interdepartmental Committee on Drug Use and Why no performance bonds are required under section 602b---. "Introduction-The Psychology, Philosophy, Mortality and Number of resident patients in State and local government mental "The Successful Treatment of Narcotic Addiction With Anti- Memorandums from Herbert H. Rozoff Associates Inc., Chicago, "Study sees glue sniffing as worse than pot"-by Gerry Keir.. National Association of Chain Drug Stores, Robert J. Bolger, executive vice president, statement. National Association of Retired Civil Employees, Thomas G. Walters, president, statement.. New York Academy of Medicine, John L. Pool, M.D., president, letter dated March 13, 1970, to Chairman Jarman, with attachments Nix, J. T., M.D., Ph. D., medical research director Nix Foundation for Medical Research and member, Louisiana Narcotics Rehabilitation Commission, letter dated March 23, 1970, to Representative Hale Boggs, with forwarding letter to Chairman Staggers-O'Donnell, John A., University of Kentucky, Department of Sociology and Rural Sociology, letter dated Febraury 13, 1970, to Congressman Watts of Kentucky, with forwarding letter to Chairman Staggers-- Pepper, Hon. Claude, a Representative in Congress from the State of Florida: Amendment No. 451 to S. 3246_ Page 94 712 391 395 388 400 804 814 221 219 797 814 825 800 830 591 "Crime in America-Why 8 Billion Amphetamines?", hearings 595 657 585 469 Federal-State cooperation in drug abuse enforcement.. Salk Institute, Joseph E. Slater, president, and Jacob Bronowski, Di- Sargent, Thornton, III, Ph. D., Berkelye, Calif., letter dated February Wisconsin Department of Health and Social Services, Arnold M. 853 836 849 751 |
0 Atsauksmes Atsauksmes netiek pārbaudītas, taču Google meklē viltus saturu un noņem to, ja tāds tiek identificēts. Rakstīt atsauksmi |